Join Growin Stock Community!

Gossamer bio, inc.GOSS.US Overview

US StockHealthcare
(No presentation for GOSS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GOSS AI Insights

GOSS Overall Performance

GOSS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GOSS Recent Performance

-2.85%

Gossamer bio, inc.

0.05%

Avg of Sector

-0.31%

S&P500

GOSS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GOSS Key Information

GOSS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GOSS Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Price of GOSS

GOSS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GOSS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.67
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.23
PB Ratio
2.66
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-354.50%
Revenue Growth (YoY)
-58.17%
Profit Growth (YoY)
-58.17%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.67
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.23
PB Ratio
2.66
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-354.50%
Revenue Growth (YoY)
-58.17%
Profit Growth (YoY)
-58.17%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is GOSS's latest earnings report released?

    The most recent financial report for Gossamer bio, inc. (GOSS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GOSS's short-term business performance and financial health. For the latest updates on GOSS's earnings releases, visit this page regularly.

  • What is the operating profit of GOSS?

    According to the latest financial report, Gossamer bio, inc. (GOSS) reported an Operating Profit of -49.11M with an Operating Margin of -369.44% this period, representing a decline of 44.8% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is GOSS's revenue growth?

    In the latest financial report, Gossamer bio, inc. (GOSS) announced revenue of 13.29M, with a Year-Over-Year growth rate of 40.23%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does GOSS have?

    At the end of the period, Gossamer bio, inc. (GOSS) held Total Cash and Cash Equivalents of 8.93M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does GOSS go with three margins increasing?

    In the latest report, Gossamer bio, inc. (GOSS) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -369.44%%, and net margin of -362.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess GOSS's profit trajectory and future growth potential.

  • Is GOSS's EPS continuing to grow?

    According to the past four quarterly reports, Gossamer bio, inc. (GOSS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.21. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GOSS?

    Gossamer bio, inc. (GOSS)'s Free Cash Flow (FCF) for the period is -36.17M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 12.91% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.